GLP-1 Coverage & Costs in Connecticut (2026)
$79/month (Embody, compounded semaglutide, monthly plan) is the lowest monthly-plan price we have recorded among the programs on this page. Embody lists 48 states and our records do not name them, so confirm Connecticut at intake.
The lowest recorded compounded tirzepatide price is $129/month (Embody, monthly plan). Among programs recorded as available in all 50 states, the lowest is $139/month (AgelessRx, compounded semaglutide, monthly plan). 6 of the 49 programs listed have no recorded price. Recorded prices cover medication and known program fees, not a verified total.
Connecticut Medicaid Coverage for GLP-1
Medicaid: not covered as of January 2026 (KFF)
KFF's map lists Connecticut as not covering GLP-1s for obesity under fee-for-service as of January 2026. KFF notes the state reported covering one or more weight-loss drugs, but no GLP-1s. Rules and later changes are not on that map, so confirm with the state Medicaid agency or your plan.
- Source: KFF, Medicaid Coverage of and Spending on GLP-1s, Figure 1 (January 16, 2026). Read 2026-11-06.
Your Options in Connecticut:
- Telehealth programs: recorded compounded prices from $79/month on a monthly plan, where the program serves Connecticut
- Commercial or employer insurance: check your plan's drug list and prior authorization rules
- Medicare GLP-1 Bridge for eligible Part D enrollees (see below)
Connecticut Medicaid GLP-1 Prescriptions in 2025
174,430
#16
$199.9 million
Ozempic
Connecticut Medicaid paid for 174,430 GLP-1 prescriptions in 2025, 1.5% of the 11.26 million paid nationally and number 16 of 51 (50 states and DC). It reimbursed pharmacies $199.9 million before manufacturer rebates, about $1,146 per prescription, and the most-filled product was Ozempic. These counts include diabetes prescriptions, not only weight loss. Wegovy, Zepbound and Saxenda, the brands approved for chronic weight management, made up 5,475 of those prescriptions (3.1%). Wegovy and Zepbound also carry other approved uses, so this is an upper bound on weight-loss use, not a count of it.
From 2021 to 2025, Connecticut Medicaid GLP-1 prescriptions went from 53,333 to 174,430, 3.3 times the 2021 count. From 2024 to 2025 the count fell by 39,234.
53,333
86,952
154,757
213,664
174,430
| Product | CT Medicaid prescriptions, 2025 | Share |
|---|---|---|
| Ozempic | 101,853 | 58.4% |
| Mounjaro | 50,327 | 28.9% |
| Trulicity | 13,087 | 7.5% |
| Zepbound | 3,350 | 1.9% |
| Rybelsus | 3,083 | 1.8% |
| Wegovy | 2,125 | 1.2% |
| Victoza | 356 | 0.2% |
| Liraglutide (generic) | 249 | 0.1% |
Source: CMS State Drug Utilization Data, 2025 (updated July 13, 2026), fee-for-service and managed care, all four quarters, compiled in our network's PriceTracker GLP-1 state table (read October 4, 2026); 2021 to 2024 summed by us from CMS's own yearly datasets with the same method, read November 9, 2026. CMS hides rows under 11 prescriptions, so small counts are slightly low. CMS publishes no per-enrollee rate here, so a total reflects the size of the program as much as use.
Connecticut Employee Plan and Insurer GLP-1 Rules
We have not read the Connecticutstate employee health plan's own documents, so we do not state whether it covers GLP-1s for weight loss. State employees can ask their benefits office or check the plan's drug list.
We have no Connecticutinsurer policy on record yet. Most commercial plans decide GLP-1 coverage plan by plan, so the employer's choice matters as much as the insurer.
Comparing self-pay programs in Connecticut?
2-minute quiz: filter by budget and medication preference.
Telehealth Programs to Check for Connecticut
We list 49 programs here. 21 are recorded as available in all 50 states. 7 more publish their own state list, summarized below for Connecticut. The rest record a state count without naming the states, so confirm Connecticut with the program at intake before you pay.
What Programs' Own Pages Say About Connecticut
8 of the 8 programs whose own pages name the states they serve include Connecticut: Willow, SnagRx, Strut Health, MangoRx, Wellorithm, MEDGm, TelosRx, Trimi. Pages read November 9, 2026. This is what each seller states about availability, not a licensing check.
| Program | Connecticut |
|---|---|
| Willow | Serves CT |
| SnagRx | Serves CT |
| Strut Health | Ships to CT |
| MangoRx | Ships to CT |
| Wellorithm | Serves CT |
| MEDGm | Serves CT |
| TelosRx | Serves CT |
| Trimi | Serves CT |
Trimi's state table lists Connecticut as served through the Arora Health network. Visit format there: Online intake reviewed by a licensed provider; no in-person visit required. The telehealth law it cites for Connecticut is Conn. Gen. Stat. 19a-906(b)(1). That citation is Trimi's, not our legal reading. Trimi state table, read November 9, 2026.
Programs on Our List, in Published Order
Compounded GLP-1 care with one-month and prepaid plans
Personalized GLP-1 consultations with tailored prescriptions and ongoing physician support
Affordable compounded semaglutide from $119/mo with free shipping and health coaching
Personalized GLP-1 weight loss with licensed providers and nationwide coverage
45 more programs on our list: 19 recorded as available in all 50 states, 7 with a state list shown in the table above, and 19 with a state count but no published list we have read. Compare all of them side by side.
Estimated GLP-1 Costs in Connecticut
Telehealth (Compounded)
$79 to $399/moRecorded monthly-plan prices for compounded semaglutide and tirzepatide. Availability varies by program, so confirm your state at intake.
Wegovy
Brand prices with and without insurance.
Zepbound
List, LillyDirect and savings card prices.
No insurance
Self-pay GLP-1 options without coverage.
The compounded range is our recorded monthly-plan prices, the same in every state. Brand and insurance costs depend on the plan, so we link the pages that carry their sources. Compounded medications are not FDA-approved.
Medicare Part D GLP-1 Claims in Connecticut, 2024
Connecticut prescribers wrote 265,056 Medicare Part D GLP-1 claims in 2024, number 27 of 51, with $355.7 million in gross drug cost before rebates. Ozempic led with 138,165 claims for 25,910 enrollees. Wegovy had 3,061 claims. Part D did not pay for weight loss alone in 2024, so these fills are for diabetes and other approved uses.
| Product | CT Part D claims | Enrollees |
|---|---|---|
| Ozempic | 138,165 | 25,910 |
| Mounjaro | 61,351 | 11,063 |
| Trulicity | 44,587 | 8,876 |
| Rybelsus | 12,842 | 3,343 |
| Wegovy | 3,061 | 778 |
| Victoza | 2,378 | Not given |
| Bydureon Bcise | 1,929 | 430 |
| Liraglutide | 613 | 244 |
| Byetta | 130 | 29 |
Source: CMS Medicare Part D Prescribers by Geography and Drug, 2024 (updated May 21, 2026), state rows, read November 9, 2026. The state is the prescriber's. Claims include refills, and enrollees are not added across products because one person can fill two.
Medicare GLP-1 Bridge Program in Connecticut
The Bridge is national, so the rules are the same in Connecticut as everywhere: eligible Part D enrollees pay $50/month for Foundayo, Wegovy or Zepbound KwikPen, subject to BMI rules and exclusions. Medicare fact sheet.
$50/mo
July 1, 2026
Dec 31, 2027
How Connecticut Compares to Other Northeast States
Medicaid coverage of GLP-1s for obesity is optional for states, so the answer differs by state. Here is how Connecticut and its neighbors in the Northeast are recorded:
| State | Medicaid and GLP-1s for obesity | Medicaid GLP-1 Rx, 2025 |
|---|---|---|
| Connecticut (this page) | Not covered | 174,430 |
| Massachusetts | Not covered | 399,014 |
| New Jersey | Not covered | 165,515 |
| New York | Not covered | 815,882 |
| Pennsylvania | Not covered | 843,743 |
Our recorded telehealth prices are not state-specific: $79 to $399/month on monthly plans. Medicaid and marketplace coverage is what varies.
KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026. Managed care plans may differ. Later counts may be lower: The RX Index, an independent tracker, listed 11 in a July 10, 2026 snapshot and says that is not a current national count. Sources read November 6, 2026. Policies change, so confirm with your state Medicaid agency or plan.
If Your Insurance Denies GLP-1 Coverage in Connecticut
Commercial plans offer an internal appeal, then external review; Connecticut Medicaid enrollees can ask for a fair hearing. The denial letter names the deadlines.
How to Check Your Specific Plan in Connecticut
- Connecticut Medicaid: Medicaid: not covered as of January 2026 (KFF). Ask your Medicaid plan for its drug list and prior authorization rules, or find the state agency on Medicaid.gov's state contacts.
- State employees: we have not read the plan's documents; ask the benefits office.
- Any other plan: call the number on your card and ask whether Wegovy or Zepbound is covered for weight loss, which tier it sits on, and what prior authorization needs. Get the answer in writing.
Find the Right GLP-1 Provider in Connecticut
Answer a few questions and we'll match you with the best GLP-1 program for your budget, insurance, and goals in Connecticut.
Frequently Asked Questions — Connecticut
Does Connecticut Medicaid cover GLP-1 medications for weight loss?
How many GLP-1 prescriptions did Connecticut Medicaid pay for in 2025?
How many Medicare Part D GLP-1 claims were there in Connecticut in 2024?
What is the cheapest way to get GLP-1 medication in Connecticut?
Which online GLP-1 programs serve Connecticut?
Does Medicare cover GLP-1s in Connecticut?
Ready to start?
Compare the recorded costs, sources and evidence gaps for 52 listed providers. Confirm current terms with the provider before enrolling.